THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
12 December 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Result of General Meeting
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, announces that at the General Meeting of the Company held earlier today, all resolutions were duly passed by shareholders.
Proxy votes received were as follows:
| Resolution No. | Resolution Name | % of Votes For | % of Votes Against | Total Votes Cast (Excluding Withheld) | Number of Votes Withheld |
| 1 Special | To authorise the withdrawal of the admission to trading on the AQSE Growth Market of the ordinary shares of the Company | 98.82 | 1.18 | 1,969,048,507 | 472,421 |
| 2 Special | To reregister the Company as a private limited company | 98.82 | 1.18 | 1,969,048,507 | 472,421 |
| 3 Special | To adopt new articles | 98.82 | 1.18 | 1,969,048,507 | 472,421 |
Where an issuer has a controlling shareholder, the resolution for the withdrawal of the ordinary shares of the Company from trading on the AQSE Growth Market must also be approved by a majority of independent shareholders. Set out below are the proxy votes received, excluding Charles Morgan, Melissa Sturgess and Jeremy Sturgess-Smith,:
| Resolution No. | Resolution Name | % of Votes For | % of Votes Against | Total Votes Cast (Excluding Withheld) | Number of Votes Withheld |
| 1 Special | To authorise the withdrawal of the admission to trading on the AQSE Growth Market of the ordinary shares of the Company | 97.31 | 2.69 | 867,354,599 | 472,421 |
Accordingly, further to the announcement of 24 November 2025, the Proposed withdrawal of the ordinary shares of the Company from trading on the AQSE Growth Market will proceed, with the last day dealings on 21 December 2025 and with cancellation of admission effective at 8.00 a.m. on 22 December 2025.
About Ananda Pharma
Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.
For more information, please visit our website:
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
-Ends-
For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.
| ANANDA PHARMA PLC | +44 (0)7463 686 497 |
| |
|
| Chief Executive Officer | |
| Melissa Sturgess | |
| | |
| Finance Director | |
| Jeremy Sturgess-Smith | |
|
| |
| SP ANGEL CORPORATE FINANCE LLP | |
|
| |
| Corporate Finance | +44 (0)20 3470 0470 |
| Richard Morrison | |
| Josh Ray | |
|
| |
| Corporate Broking | +44 (0)20 3470 0534 |
| Vadim Alexandre | |
| Abigail Wayne | |
| Rob Rees
| |
| | |
https://investors.anandapharma.co.uk/link/P4x1zP
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
